Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 1
2012 4
2013 4
2014 2
2017 2
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Mutations targeting the coagulation pathway are enriched in brain metastases.
Richichi C, Fornasari L, Melloni GEM, Brescia P, Patanè M, Del Bene M, Mustafa DAM, Kros JM, Pollo B, Pruneri G, Sciandivasci A, Munzone E, DiMeco F, Pelicci PG, Riva L, Pelicci G. Richichi C, et al. Among authors: sciandivasci a. Sci Rep. 2017 Jul 26;7(1):6573. doi: 10.1038/s41598-017-06811-x. Sci Rep. 2017. PMID: 28747664 Free PMC article.
Pegylated Liposomal Doxorubicin (Caelyx®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.
Dellapasqua S, Trillo Aliaga P, Munzone E, Bagnardi V, Pagan E, Montagna E, Cancello G, Ghisini R, Sangalli C, Negri M, Mazza M, Iorfida M, Cardillo A, Sciandivasci A, Bianco N, De Maio AP, Milano M, Campennì GM, Sansonno L, Viale G, Morra A, Leonardi MC, Galimberti V, Veronesi P, Colleoni M. Dellapasqua S, et al. Among authors: sciandivasci a. Curr Oncol. 2021 Dec 7;28(6):5167-5178. doi: 10.3390/curroncol28060433. Curr Oncol. 2021. PMID: 34940072 Free PMC article. Clinical Trial.
Safety and efficacy study of metronomic vinorelbine, cyclophosphamide plus capecitabine in metastatic breast cancer: A phase II trial.
Montagna E, Palazzo A, Maisonneuve P, Cancello G, Iorfida M, Sciandivasci A, Esposito A, Cardillo A, Mazza M, Munzone E, Lai A, Goldhirsch A, Colleoni M. Montagna E, et al. Among authors: sciandivasci a. Cancer Lett. 2017 Aug 1;400:276-281. doi: 10.1016/j.canlet.2017.01.027. Epub 2017 Jan 26. Cancer Lett. 2017. PMID: 28131905 Clinical Trial.
Prognostic relevance of peritumoral vascular invasion in immunohistochemically defined subtypes of node-positive breast cancer.
Munzone E, Bagnardi V, Rotmensz N, Sporchia A, Mazza M, Pruneri G, Intra M, Sciandivasci A, Gentilini O, Luini A, Viale G, Veronesi P, Colleoni M. Munzone E, et al. Among authors: sciandivasci a. Breast Cancer Res Treat. 2014 Aug;146(3):573-82. doi: 10.1007/s10549-014-3043-2. Epub 2014 Jul 10. Breast Cancer Res Treat. 2014. PMID: 25007961
Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report.
Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, Curigliano G, Colleoni M, Goldhirsch A, Nolè F. Aurilio G, et al. Among authors: sciandivasci a. Breast J. 2012 Sep;18(5):470-4. doi: 10.1111/j.1524-4741.2012.01278.x. Epub 2012 Jul 25. Breast J. 2012. PMID: 22827581 Clinical Trial.
Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, Curigliano G, Goldhirsch A, Nolè F. Aurilio G, et al. Among authors: sciandivasci a. Acta Oncol. 2013 Nov;52(8):1649-56. doi: 10.3109/0284186X.2012.754990. Epub 2013 Jan 17. Acta Oncol. 2013. PMID: 23327413
15 results